CERS News and Press, Cerus Corporation From 07/14/22

Cerus Corp. presents us with softening fundamentals that look unattractive against the current macro backdrop. Investors are rewarding bottom line fundamentals in FY22 as they step up in quality, hence, CERS misses the bill on this front. Balancing the risk/reward calculus are its...

The Ark Innovation ETF (NYSEMKT: ARKK) has been performing dreadfully this year, down 53% thus far. That's much worse than the S&P 500 and its 19% loss. The fund's focus has been on growth-oriented companies, many of which aren't posting strong and consistent profits. And as...

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. “We are pleased to welcome Dr. Shan to Cerus’ Board of...

Gainers: Seres Therapeutics (MCRB) +8%. Sana Biotechnology (SANA) +5%. Aziyo Biologics (AZYO) +4%. eXp World Holdings (EXPI) +4%. Aurora Innovation (AUR) +3%. Losers: Trip.com Group (TCOM) -9%. Xenon Pharmaceuticals (XENE) -8%. Accolade (ACCD) -6%. Ikena Oncology (IKNA) -6%. Cerus (...

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2022. For over 15 years, World Blood Donor Day has helped served as an annual event to raise awareness of the crucial importance of available blood and blood products for patients around t...

Image source: The Motley Fool. Cerus (NASDAQ: CERS) Q1 2022 Earnings Call May 05, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus (CERS) Q1 2022 Earnings Call Transcript

Cerus Corporation (CERS) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Matt Notarianni – Senior Director-Investor Relations Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – ...

Cerus press release (NASDAQ:CERS): Q1 GAAP EPS of -$0.07 beats by $0.01. Revenue of $43.02M (+45.5% Y/Y) beats by $5.53M. Increasing Full-Year 2022 Product Revenue Guidance Range from $157-164 Million to $160-165 Million. At March 31, 2022, the Company had cash, cash equivalents and...

Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S. Total Revenue of $43.0 Million Grew 46% YoY in the First Quarter Product Revenue of $37.4 Million Grew 60% YoY in the First Quarter Increasing Full-Year 2022 Product...

Cerus (NASDAQ:CERS) on Tuesday signed a ten-year agreement with Germany's Fresenius Kabi for the production of INTERCEPT Blood System sets. Tuesday's new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025. Fresenius Kabi will continue producing sets for ...